Cargando…
First COVID-19 Vaccines Receiving the US FDA and EMA Emergency Use Authorization
On December 31, 2019, the Wuhan Municipal Health Commission reported an increase in the incidence of pneumonia from an unknown cause. Shortly after, SARS-CoV-2 was identified as the responsible coronavirus for the heavy progress of the disease, which can manifest itself distinctively in different in...
Autores principales: | Fortner, Andra, Schumacher, David |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Applied Systems srl
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8101362/ https://www.ncbi.nlm.nih.gov/pubmed/33969180 http://dx.doi.org/10.15190/d.2021.1 |
Ejemplares similares
-
Lutathera(®): The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy
por: Hennrich, Ute, et al.
Publicado: (2019) -
The Biosimilar Landscape: An Overview of Regulatory Approvals by the EMA and FDA
por: Gherghescu, Ioana, et al.
Publicado: (2020) -
Elements of Regulatory Dissonance: Examining FDA and EMA Product Labeling of New Vaccines (2006–2018)
por: Seo, Yurim, et al.
Publicado: (2020) -
US FDA erratic approach to placebo-controlled trials after issuing an emergency use authorization for a COVID-19 vaccine
por: Dal-Ré, Rafael
Publicado: (2021) -
Availability of Authorizations from EMA and FDA for Age-Appropriate Medicines Contained in the WHO Essential Medicines List for Children 2019
por: delMoral-Sanchez, Jose-Manuel, et al.
Publicado: (2020)